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Abstract 
Faecal immunochemical tests for haemoglobin (FIT), as an adjunct to clinical 
information, assist in the triage of patients presenting in primary care with lower 
abdominal symptoms. Controversy remains regarding whether and which qualitative 
and quantitative FIT can be used, which groups of patients would benefit most from 
FIT, whether FIT should be done in primary and/or secondary care, and how FIT 
should be incorporated into diagnostic pathways. Controversy also exists as to the 
optimum cut-off used for referral for colonoscopy. A single sample of faeces may be 
sufficient. Reporting of results requires consideration. FIT provide a good rule in test 
for colorectal cancer and a good rule out test for significant bowel disease, but robust 
safety-netting is required for patients with negative results and ongoing symptoms. 
Risk scoring models have been developed, but their value is unclear as yet. Further 
evaluation of these topics is required to inform good practice.  
Introduction 
 
Faecal immunochemical tests for haemoglobin (FIT) are now widely used in  
asymptomatic colorectal (bowel) cancer screening since widely perceived as the 
best currently available non-invasive approach:  participants with positive results are 
referred for further investigation, usually colonoscopy.1 Possibly because of (a) the 
positive publicity surrounding such programmes, (b) the information given that 
participants who experience lower abdominal symptoms between screening 
episodes should seek medical care and (c) the influence of well-known individuals in 
the media,2 the demand for colonoscopy has risen further over recent times.  In 
addition, because more bowel disease is found, an increased requirement for 
colonoscopic surveillance after treatment has occurred, although there are early 
indications that FIT might be useful in this clinical setting as well as others.3 Further, 
there have been local, regional and national efforts in many countries encouraging 
people with abdominal symptoms to seek urgent medical attention in primary care, 
again leading to further demands on colonoscopy services.4   
 
However, colonoscopy is often a limited resource and, in consequence, it would be 
of much benefit if a simple, inexpensive investigation would aid in deciding which of 
the many patients presenting with symptoms, particularly in primary care, would 
benefit from colonoscopy and which would not.  This is particularly germane since, 
as pointed out some time ago by Jellema et al5 and very well documented more 
recently by Vega et al,6 diagnosis is a challenge, since there are often no specific 
symptoms and lower abdominal symptoms are very common and mostly related to 
problems other than significant bowel disease (SBD), which includes colorectal 
cancer (CRC), advanced adenoma (AA) that are sometimes precursors of CRC, and 
inflammatory bowel disease (IBD). Indeed, according to the National Institute for 
Health and Care Excellence (NICE) in England, common symptoms have a positive 
predictive value (PPV) for CRC of only 3-4%.7 Thankfully, there is ever growing 
evidence that FIT can be used to assist in the triage of patients presenting with 
symptoms of lower bowel disease. 
 
FIT in assessment of patients with lower abdominal symptoms 
 
The evidence for the successful application of FIT in assessment of patients 
presenting in primary care with lower abdominal symptoms, and patients being seen 
in secondary care clinics after referral, has been very well documented in a number 
of recent reviews.8-11 Therefore, the fine details of the individual studies will not be 
repeated in detail in this review. Although it is known that there are a number of real-
world pilots, feasibility studies and evaluations of FIT in the assessment of 
symptomatic patients underway and publications on this topic are in press or in 
preparation, there appears to have been only one further relevant publication12 since 
the most recent comprehensive review.11 This study investigated the value of a 
quantitative FIT in the diagnostic process of CRC and other SBD in individuals 
presenting with low risk symptoms in general practice, FIT being used as a rule-in 
test on patients aged ≥ 30 years with the faecal haemoglobin concentration (f-Hb) 
cut-off for referral to colonoscopy being 10 µg Hb/g faeces: 3462 FIT were performed 
and 540 (15.6%) had positive results. Of these, 51 (PPV: 9.4%) individuals with a 
positive FIT result were diagnosed with CRC and 73 (PPV: 13.5%) with other SBD. 
The false negative test result rate for CRC was < 0.1%. It was concluded that FIT 
may be used as a supplementary diagnostic test in general practice in the diagnostic 
process of CRC and other SBD in individuals with low risk of CRC.  
 
Even though it has been documented by NICE,13 a highly respected developer of 
guidelines, that quantitative FIT are recommended for adoption in primary care to 
guide referral for suspected CRC in people without rectal bleeding who have 
unexplained symptoms but do not meet the criteria for a suspected cancer pathway 
referral outlined in the NICE NG12 guideline,7 and that results should be reported 
using a f-Hb cut-off of 10 µg Hb/g faeces, many controversies still exist: a number of 
these will be addressed in this review. 
 
Qualitative or quantitative FIT 
 
FIT are available in two formats.14 Qualitative FIT give a dichotomous, 
positive/negative result, usually using lateral-flow immunochromatographic cassettes 
or strips. Quantitative FIT usually involve automated immunoturbidimetry on small 
bench-top dedicated analytical systems and provide a numerical estimate of the f-
Hb: such examinations can also be performed on larger routine laboratory medicine 
automated systems. As detailed previously,10,11 both constructs have been used to 
evaluate the use of FIT in assessment of patients with symptoms. Some of the 
advantages and disadvantages of qualitative and quantitative FIT are listed in Table 
1. 
 
Selecting a faecal immunochemical test 
 
Although there are a large number of qualitative15 and qualitative16 FIT available, it 
could be argued that the available evidence suggests that both qualitative and 
quantitative FIT appear to give somewhat similar clinical outcomes10 and both could 
be used in assessment of patients presenting with lower abdominal symptoms if the 
disadvantages of the two rather different approaches were carefully kept in mind. 
However, it must be noted that the data available to support the use of FIT in this 
clinical setting was generated with only very few of the qualitative15 and 
quantitative16 FIT available. There are more data on quantitative than qualitative FIT 
and only the former were recommended by NICE.13 In consequence, it has been 
advocated that assessment of the benefits and harms of qualitative FIT being done 
by people in their own homes should be investigated,17 as should the use in general 
practice and in secondary healthcare settings, particularly in gastroenterology and 
other clinics evaluating patients before colonoscopy.10,11  
 
It is important to note that the numerical results generated using different FIT may 
not be the same. Three quantitative FIT systems were recommended in NICE DG30, 
namely the OC-Sensor (Eiken Chemical Co. Ltd, Tokyo, Japan), the HM-JACKarc 
(Kyowa Medex Co., Ltd, Tokyo, Japan) and FOB-Gold (Sentinel Diagnostics, Milan, 
Italy);13 however, the evidence gathered to support the recommendation of these 
three FIT systems clearly does show differences in the clinical outcomes obtained.  
The main reason for the differences is probably that polyclonal antibodies are used, 
which may react differently to the spectra of intact haemoglobin (Hb) and early 
degradation products present in faecal samples collected for analysis.  In addition, 
the analytical performance characteristics of the FIT systems show  a number of 
marked differences, for example, the analytical range, the limit of detection, the 
lowest f-Hb that can be reliably distinguished from a sample with no f-Hb, and the 
limit of quantitation, the lowest f-Hb that can be reliably measured, differ between 
these three quantitative FIT systems.18   In addition,  there are a number of pre-
analytical and analytical aspects which differ between FIT and these include lack of 
harmonisation of the specimen collection devices, the intrinsic heterogeneity and 
variable consistency of faecal samples and the effect of these variables on faecal 
collection, the different recommended techniques for collection of faeces and the fact 
that no primary reference material or method is currently available to standardise 
FIT.19  Further, a very relevant concern is the transferability of already published data 
over time and geography: manufacturers of FIT continually evolve their products 
and, in consequence, outcomes may not be comparable over time. An example of 
change over time is that two of the quantitative FIT recommend by NICE13 have had 
improvements made to their buffers, supposedly to increase the stability of any 
haemoglobin present prior to analysis.20,21  
 
Although there are a number of studies comparing different FIT in asymptomatic 
population-based screening applying different strategies,22 which do demonstrate 
differences between systems when the same cut-off f-Hb is used for referral to 
colonoscopy, which are minimised if the same positivity is used,23-5 there seem no 
head to head comparisons of FIT in assessment of patients with symptoms. This 
would be of considerable interest, since the same FIT are used in screening and 
assessment of the symptomatic and it has been amply demonstrated15,16 that there 
are many differences between available FIT used in screening. 
 
Deciding which patients should undertake a FIT 
 The clinical outcome characteristics will depend very much on the type of patients 
who have provided faecal samples for FIT analysis. The spectra of patients 
examined have varied from study to study.10,11 NICE DG30 specifically states,13 as 
detailed above, that FIT are to be applied in what might be termed low risk patients 
and those patients who have rectal bleeding and meet the criteria for a suspected 
cancer pathway referral outlined in NICE NG127 should be referred for further 
investigation without FIT.  However, most evaluations have assessed the value of 
FIT in quite mixed populations including those at high risk of CRC and even those 
undergoing surveillance for previous disease.26 In addition, most studies, except for 
that of Mowat et al27 and Juul et al12 have not evaluated the use of FIT in primary 
care, but have examined patients who were already referred for colonoscopy through 
a variety of clinical pathways with different criteria for referral. Further studies on the 
routine application of FIT in primary care are urgently required, since this seems to 
be the most appropriate sector in which FIT should be requested. However, studies 
on the appropriate uses of FIT in secondary care, such as in gastroenterology 
clinics, would also be of considerable interest. 
 
In addition, there has been some controversy about how FIT should be integrated 
into diagnostic pathways.  One study, following on directly from an evaluation of 
point of care (POC) FIT and calprotectin in patients with symptoms,28 developed a 
multivariable diagnostic model for SBD with routine clinical information and 
subsequently extended this with faecal calprotectin testing and/or qualitative POC 
FIT.29 The results were said to underscore that a positive f-Hb result already implies 
the need for referral and that clinical data do not add much. However, it was 
suggested that these data are informative when the f-Hb result is negative.  It was 
concluded that a diagnostic strategy with routine clinical data and f-Hb alone may 
safely rule out SBD and prevent unnecessary endoscopy referral in approximately 
one-third of patients. A contrasting editorial suggested that a single quantitative f-Hb 
result, without any clinical information, could be sufficient to decide whom to refer for 
colonoscopy and, because of the significant overlap of symptoms in those with and 
without SBD, could be the primary investigation performed.30 This thesis has been 
supported in a recent study which compared the utility of FIT as the initial 
investigation with the original 2015 NICE NG12 symptom based guidelines.31 Data 
from three studies done in Scotland were included and overall diagnostic accuracy 
was also estimated by the area under the receiver operating characteristic (ROC) 
curve (AUC). The AUC for CRC was 0.85 for FIT versus 0.65 for NG12 and, for 
SBD, the AUC was 0.73 for FIT versus 0.56 for NG12.  It was concluded that f-Hb 
provided a good rule-out test for SBD and had significantly higher overall diagnostic 
accuracy than the 2015 NG12 guidelines.7 
 
Other approaches are possible10 and, according to a recent review on setting up a 
service for FIT for assessment of symptomatic patients, there appears to be no “best 
practice” that can be detailed at this particular time:19 reports on the results of the 
use of FIT for the routine assessment of patients in primary care are awaited with 
interest, but informal current consensus seems to be that the f-Hb found should be 
taken into account along with symptoms and clinical findings, particularly chronic 
diarrhoea and the presence of an abdominal mass, and the results of the full blood 
count, particularly the detection of anaemia, as recently advocated by Hogberg et 
al.32 
 Selecting the cut-off faecal haemoglobin concentration (f-Hb) used for referral 
for colonoscopy 
 
A number of the evaluations of the use of quantitative FIT in assessment of the 
symptomatic have explored the relationship between f-Hb and clinical outcomes.  
Since it is very well documented that f-Hb is directly related to the severity of 
colorectal disease, and as confirmed recently,33 it is not surprising that, as the f-Hb 
cut-off is lowered, the sensitivity increases and the specificity decreases. A good 
example is provided in a supplementary table in the study of Rodríguez-Alonso et 
al,34 where, at f-Hb cut-offs > 0, > 10, >15 and > 20 µg Hb/g faeces, sensitivity for 
CRC was 100, 96.7, 96.7 and 93.3% with specificity of 43.3, 79.8, 83.1 and 86.1% 
and, for advanced neoplasia (AN: CRC + AA), sensitivity was 81.2, 61.7, 57.1 and 
53.4%, while specificity was 45.5, 83.4, 86.6 and 89.4%.  It is important to note that, 
at 20 µg Hb/g faeces, a commonly used cut-off in asymptomatic population-based 
screening, and as used by Cubiella et al,35 a small number of cases of CRC are 
missed. This has also been shown for AA and IBD at f-Hb cut-offs of 10 µg Hb/g 
faeces, as recommended by McDonald et al36 and Godber et al.37 This missing of 
cases of SBD was also found by Mowat et al27 with a f-Hb cut-off of 10 µg Hb/g 
faeces, but who also investigated “detectable” f-Hb as a cut-off (defined as > 0 µg 
Hb/g faeces) achieving sensitivities of 100, 82.5 and 85.3% for CRC, AA and IBD 
respectively.  Similarly, Widlak et al stated that an undetectable FIT haemoglobin is 
sufficiently sensitive to exclude CRC, but they defined “undetectable” as f-Hb < 7 µg 
Hb/g faeces, the LoQ of the FIT system used.38  
 
The publications on FIT in the assessment of patients with symptoms clearly 
demonstrate the current controversy of which f-Hb cut-off to use and also the 
dilemma of how to report the results of FIT analyses. This has been addressed in 
detail recently39 and a series of proposals made including the following:40 
 
 f-Hb concentrations should not be reported to more significant figures than 
whole integers, 
 
 f-Hb concentrations less than the limit of detection (LoD) of the FIT analytical 
system should be termed “not detected” or “undetectable”, 
 
 for academic use: f-Hb greater than the LoD could advantageously be 
documented, 
 
 for routine clinical use: numerical f-Hb should be reported only when greater 
than the limit of quantitation (LoQ): f-Hb less than the LoQ (x) should be 
reported as < x μg Hb/g faeces and 
 
 if a more sophisticated reporting system is required, one option is to report: 
 
o f-Hb < LoD = f-Hb not detected 
o LoD < f-Hb < LoQ = f-Hb detected 
o f-Hb  ≥ LoQ = report the found f-Hb 
 
Adherence to these proposals would result in harmonisation of the reporting of f-Hb 
data, which should facilitate understanding and transferability of information across 
geography and time. 
 
A further controversy is whether the high sensitivity makes FIT a good rule-in test for 
CRC or the high negative predictive value (NPV) shown in many studies on use of 
FIT in assessment of the symptomatic10,11 demonstrates that FIT provides a good 
rule out investigation for SBD. In reality, f-Hb in patients presenting in primary carer 
with lower abdominal symptoms could be considered as a continuous variable. The 
most important use in colonoscopy constrained countries is likely to be to stop 
patients with vague symptoms and unlikely to have SBD being referred for 
colonoscopy. If the f-Hb is lower than the selected f-Hb cut-off and if the patient does 
not have what are sometimes termed red flag symptoms, then the risk of SBD is 
small:  however, this does not simply mean informing the patient nothing is wrong. 
Many lower abdominal symptoms are transient, so it might be satisfactory to leave 
these patients without any immediate further investigation but, for others who 
continue to have symptoms, it is obligatory to have robust safety-netting procedures 
in place as recently described in a review of FIT in patients with symptoms,41 
including watching and waiting, referral to gastroenterology in secondary care, and 
perhaps a repeat FIT, although there is no evidence to date that this is useful. This is 
important since, as discussed above, a few cases of CRC may be missed in addition 
to a few more cases of AA and IBD. Moreover, since it is well documented that f-Hb 
is related to disease severity,33 the higher the f-Hb, the greater the risk of SBD. In 
consequence, those with very high f-Hb might benefit from more rapid referral to 
colonoscopy than those who have slightly elevated f-Hb. 
 How many faecal samples should be taken for FIT? 
 
It is dogma that some neoplastic lesions in the colon bleed intermittently and so it is 
also dogma that more than one faecal sample should be collected. Although there is 
considerable literature on one versus two samples in asymptomatic population 
screening, the literature on the effect of number of FIT samples in assessment of 
patients with symptoms is sparse.  A recent study assessed the use of three 
samples in patients with CRC and adenomas with high grade dysplasia (HGD) that 
initially presented with symptoms to primary care and completed FIT.42 Of 195 
patients, 160 delivered three FIT. Using the 139 cases in which at least one sample 
was positive, the likelihood of detecting a positive sample upon analysis of only one 
of the three samples was 0.91, indicating that 13 positive cases may have been 
missed. It was concluded that use of one sample instead of three samples may 
result in missing about 10% of symptomatic CRC and adenomas with HGD. 
Unfortunately, this study was done with a visually read qualitative FIT and dipstick 
test, with f-Hb cut-off of 25–50 µg Hb/g faeces, rather higher than f-Hb cut-offs used 
in the published studies using quantitative FIT. It may be unsurprising, therefore, that 
cases of SBD were missed. Auge et al26 examined the clinical utility of one versus 
two samples for FIT samples in the detection of advanced colorectal neoplasia 
(ACRN: CRC + AA) in symptomatic patients using a quantitative FIT. It was found 
that the diagnostic yield, when two samples for FIT were collected (using f-Hb cut-off 
of 20 μg Hb/g faeces), could be achieved with one sample, albeit using a lower f-Hb 
cut-off (10 μg Hb/g faeces). With a different FIT analytical system, using two samples 
for each patient and choosing the highest result, the sensitivity for ACRN was 40.0%, 
with a specificity of 88.6%, and a similar diagnostic yield was again obtained using 
only one sample and decreasing the f-Hb cut-off.43 Moreover, when one sample and 
a 10 μg Hb/g faeces cut-off was used, it was possible to rule out the majority of 
malignant lesions. Based on this small amount of evidence, since collecting multiple 
samples involves more funding and effort and might decrease the acceptability of the 
test for patients, it is likely that one sample combined with a low f-Hb cut-off would 
provide a cost-effective and clinically efficient service for patients presenting in 
primary care. 
 
FIT alone or in combination with other variables 
 
Risk prediction models which take both symptoms and multiple risk factors into 
account might have potential to improve timely diagnosis of SBD. Williams et al44 
have systematically identified and compared the performance of models that predict 
the risk of primary CRC among symptomatic individuals: it was concluded that good 
approaches had been generated in both primary and secondary care populations. 
Most were said to contain variables that were easily obtainable in a single 
consultation. However, few of the models actually include f-Hb in the algorithm. 
Since it is well documented that f-Hb increase with age and is higher in men than 
women,45 although the actual f-Hb vary from country to country,46 Rodríguez-Alonso 
et al34 created a simple risk score for AN based upon age, gender and f-Hb. The 
points attributed to each risk factor were weighted according to their respective 
coefficients in a multiple logistic regression model and the score had a range of 0–11 
points based on the sum of the points in the individual patient.  A simple chart to 
calculate the sum was published. In the population studied, if a risk score ≥ 5 was 
considered as the referral criterion for colonoscopy, only 36.4% of would be referred; 
no cases of CRC and only 5% of AA were undetected. A more complex approach 
was developed by Cubiella et al46 using a multivariate logistic regression analysis to 
develop the model, with diagnostic accuracy of CRC detection as the main outcome: 
1572 symptomatic patients were included in the derivation cohort and 1481 in the 
validation cohorts. The final prediction model included 11 variables: age, male sex, f-
Hb ≥20 μg Hb/g faeces, blood Hb <10 g/dl, blood haemoglobin 10-12 g/dl, 
carcinoembryonic antigen ≥3 ng/ml, aspirin use, previous colonoscopy, presence of 
a rectal mass, benign anorectal lesion, rectal bleeding, and change in bowel habit. 
The AUC was 0.92. On the basis of the thresholds with 90% and 99% clinical 
sensitivity, the derivation cohort was divided into high, intermediate and low risk 
groups for CRC with PPV of 40.7, 4.4 and 0.2% respectively. It was concluded that 
the COLONPREDICT strategy developed was a highly accurate prediction model for 
CRC detection. Because of the complexity of this model, Cubiella et al went on to 
develop the faecal hemoglobin concentration, age and sex test (FAST) score with 
data from five diagnostic test accuracy studies that evaluated quantitative FIT in 
symptomatic patients referred for colonoscopy:47 1,572 and 3,976 patients were 
examined in derivation and validation cohorts, respectively. The AUC for CRC 
detection was 0.88 and 0.91 in the derivation and validation cohorts. The FAST 
score was said to an easy to calculate prediction tool, highly accurate for CRC 
detection in symptomatic patients. Other variables affect f-Hb, such as deprivation, 
49,50 and it may be that these should be examined for incorporation into future risk 
scoring strategies. However, it is clear that further research is needed to assess the 
clinical utility of these risk scoring strategies and other complex approaches before 
they can be incorporated into routine practice. 
 Conclusions 
 
Although there is much evidence from research studies that FIT, as an adjunct to 
clinical information and full blood count, can provide a very useful tool to assist with 
the triage of patients presenting in primary care with lower abdominal symptoms, 
there remain a number of issues which can only be resolved through further study 
and evaluation as FIT become more and more applied in real-world clinical 
practice.51  There remains some controversy regarding whether and which qualitative 
and quantitative FIT can be applies in this clinical setting, which particular groups of 
patients would benefit from FIT, and whether the investigation should be done in 
primary and/or secondary care settings and how it should be incorporated into 
diagnostic pathways. Controversy also exists as to the optimum f-Hb to be used for 
referral for colonoscopy, although it is known that sensitivity will increase and 
specificity decrease as the cut-off f-Hb is lowered. Harmonisation of approaches to 
defining the detectability characteristics of FIT analytical methods is required as is 
standardisation of the reporting of results. FIT, with high sensitivity, provide a good 
rule in test for CRC and, with high NPV, a good rule out test for SBD: however, no 
test is perfect and, irrespective of the f-Hb cut-off applied, a small number of CRC 
will be missed as will rather more AA and IBD: thus, robust safety-netting is required 
for patients who have negative FIT results but continue to experience symptoms. 
Some evidence exists that a single sample of faeces is sufficient in assessment of 
patients with symptoms. Risk scoring models incorporating f-Hb and other variables, 
particularly age and sex, have been developed, but further research is required as to 
their value in clinical practice. Further simple research studies on the value of FIT in 
assessment of patients with symptoms would seem somewhat redundant. What is 
required now are reports on the evaluation of the routine use of FIT in assessment of 
patients with symptoms, particularly on the controversial aspects which still remain 
as outlined here, and the many other challenges not discussed here, but explicitly 
addressed in previous reviews, including many analytical aspects concerning the 
current analysis of f-Hb.10,11,19 
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Table 1: Advantages and disadvantages of qualitative and quantitative faecal 
immunochemical tests for haemoglobin (FIT) 
Qualitative FIT 
Advantages: 
(a) supposedly simple to perform; 
(b) inexpensive, even in small numbers;  
(c) no need for analytical instrumentation;  
(d) can be done by others in health care than professionals in laboratory 
medicine;  
(e) easy to store since no refrigeration of components needed;  
(f) no calibration is needed;  
(g) integral quality monitors are always present; and 
(h) results are available for clinical decision-making within minutes.   
Disadvantages: 
(a) it is not simple to interpret faint lines on strips or cassettes;  
(b) colour develops dynamically and true negatives become positive with a 
prolonged read time and results may be falsely negative if read too early;  
(c) no quality control with an appropriate matrix is possible;  
(d) difficult and time consuming to do large numbers;  
(e) no automation generally possible, although some small readers are 
available;  
(f) usually impossible to download data directly resulting in possibilities of 
transcription mistakes;  
(g) f-Hb cut-off concentrations are set by the manufacturer, are not the same 
for different FIT and it is difficult to decide which to use in practice; and 
(h) lot-to-lot variation is possible and some acceptance quality checks are 
needed to confirm cut-off. 
Quantitative FIT 
Advantages: 
(a) high quality analyses with good reproducibility; 
(b) easy to monitor quality using total quality management techniques to 
guarantee astandards through International Standardization Organization (ISO) 
15198 accreditation; 
(c) high throughput of samples may be possible;  
(d) no visual interpretation of results;  
(e) download of data into LIS via middleware may be possible, eliminating 
transcription errors and facilitating record keeping; and 
(f) linkage with other data, for example, age and sex, may be possible and may 
be important for the future for risk scoring or monitoring; and 
(g) the cut-off f-Hb for referral for colonoscopy can be set locally. 
Disadvantages: 
a) expensive if few FIT analyses done;  
(b) need for instrumentation, installation, training, etc.;  
(c) the need to evaluate or validate for laboratory medicine accreditation 
systems and then prepare complex documentation;  
(d) difficult to decide which FIT analytical system to use since many now 
available;  
(e) only done by trained professionals in laboratory medicine;  
(f) refrigeration required for latex reagent and quality control materials and 
calibrators; and 
(g) issues around stability of haemoglobin in specimen collection devices. 
 
